Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
| Revenue (TTM) | $77.55M |
| Gross Profit (TTM) | $24.34M |
| EBITDA | $14.38M |
| Operating Margin | 17.30% |
| Return on Equity | 32.40% |
| Return on Assets | 12.00% |
| Revenue/Share (TTM) | $24.04 |
| Book Value | $14.95 |
| Price-to-Book | 4.37 |
| Price-to-Sales (TTM) | 3.03 |
| EV/Revenue | 2.66 |
| EV/EBITDA | 10.20 |
| Quarterly Earnings Growth (YoY) | 143.40% |
| Quarterly Revenue Growth (YoY) | 16.60% |
| Shares Outstanding | $3.20M |
| Float | $1.74M |
| % Insiders | 36.96% |
| % Institutions | 31.75% |
Volatility is currently expanding
Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality.
IRVINE, CA / ACCESS Newswire / April 30, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 third quarter ended March 31, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PDEX and any ticker you trade — then tracks every position and per-strategy win rate.
